Skip to main content
Signal8

BIOXYTRAN, INC (BIXT)

Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Bioxytran, Inc. logo

Bioxytran, Inc.

OTC:BIXTHealthcare
AH+0.00%$0.0247
Close$0.0247+11.26%
Mkt Cap$2.83M
EV-
Float91.09M
O/S114.7M
VOL76K sh
$ Vol$2K
RVOL0.89×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Bioxytran, Inc. logoOTC:BIXTAH$0.0247+0.00%

BIOXYTRAN, INC (BIXT) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 18 SEC filings.

Shelf registration
None on file in the filings reviewed
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
6 warrant series recorded as outstanding
Most recent offering
PIPE, closed Jul 8, 2026
Source: 10-Q filed Aug 14, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro